Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.91 | 1.93 |
NAV | ₹38.29 | ₹36.39 |
Fund Started | 12 Nov 2018 | 25 Jun 2018 |
Fund Size | ₹3197.52 Cr | ₹4917.81 Cr |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 18.48% | 21.42% |
3 Year | 20.30% | 22.75% |
5 Year | 25.42% | 26.68% |
1 Year
3 Year
5 Year
Equity | 98.52% | 98.07% |
Cash | 1.48% | 1.93% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 10.23% |
Cipla Ltd. | 8.28% |
Suven Pharmaceuticals Ltd. | 8.21% |
Ipca Laboratories Ltd. | 7.24% |
Globus Medical Inc | 6.75% |
Illumina Inc. (USA) | 5.77% |
Gland Pharma Ltd. | 4.39% |
Apollo Hospitals Enterprise Ltd. | 4.15% |
Laurus Labs Ltd. | 4.12% |
Alembic Pharmaceuticals Ltd. | 4.10% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.83% |
Cipla Ltd. | 9.28% |
Dr. Reddy's Laboratories Ltd. | 8.93% |
Divi's Laboratories Ltd. | 5.56% |
Aurobindo Pharma Ltd. | 5.05% |
Lupin Ltd. | 4.67% |
Alkem Laboratories Ltd. | 3.98% |
Gland Pharma Ltd. | 3.73% |
Mankind Pharma Ltd. | 3.22% |
Zydus Lifesciences Ltd. | 2.96% |
Name | Jay Kothari | Dharmesh Kakkad |
Start Date | 16 Mar 2018 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 12 Nov 2018 | 25 Jun 2018 |
Description
Launch Date